<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03340480</url>
  </required_header>
  <id_info>
    <org_study_id>NVP-1402-02</org_study_id>
    <nct_id>NCT03340480</nct_id>
  </id_info>
  <brief_title>The Food Effect on the Pharmacokinetics of NVP-1402</brief_title>
  <official_title>The Food Effect on the Pharmacokinetics of NVP-1402</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Navipharm Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Navipharm Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the food effect on the pharmacokinetics of NVP-1402
      in healthy male volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as randomized, open-label, single oral dose, two-treatment, two
      sequence crossover active-controlled and crossover assignment for evaluate the food effect on
      the pharmacokinetics of NVP-1402 in healthy male subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 12, 2017</start_date>
  <completion_date type="Actual">May 2, 2018</completion_date>
  <primary_completion_date type="Actual">January 8, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of plasma: Cmax</measure>
    <time_frame>up to 24 hours after administration</time_frame>
    <description>Maximum measured concentration of the analyte in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of plasma: AUClast</measure>
    <time_frame>up to 24 hours after administration</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of plasma: AUCinf</measure>
    <time_frame>up to 24 hours after administration</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of plasma: Tmax</measure>
    <time_frame>up to 24 hours after administration</time_frame>
    <description>Time from dosing to the maximum measured concentration of the analyte in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of plasma: t1/2</measure>
    <time_frame>up to 24 hours after administration</time_frame>
    <description>Terminal half-life of the analyte in plasma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>NVP-1402-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVP-1402 was administered once a day for 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVP-1402-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVP-1402 was administered once a day for 24 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP-1402</intervention_name>
    <description>Oral</description>
    <arm_group_label>NVP-1402-1</arm_group_label>
    <arm_group_label>NVP-1402-2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males

          -  No history of clinically significant medical disorder

          -  Capable of consent to participate in the study

        Exclusion Criteria:

          -  History of hypersensitive reactions to study drug or other related drugs

          -  Any significant abnormality found during screening

          -  Any significant medical history

          -  History of alcohol abuse, smoking continuously

          -  History of drug abuse

          -  Clinically significant surgery within 4 weeks prior to administration of the study
             drug

          -  Participation in another clinical trial within 3 months prior to administration of the
             study drug
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>D Seong Shin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gachon University Gil Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Navipharm</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggi-do</state>
        <zip>16209</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2017</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

